ALS, MS & Neurodegenerative Diseases: Root Causes, Progression, and Integrative Approaches (Part 1 of 2)

Overview: The Neurodegenerative Disease Spectrum

Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD), and related conditions share a common thread: progressive neuroinflammation, mitochondrial dysfunction, oxidative stress, and failure of the brain's glymphatic and immune clearance systems. While each disease has a distinct pathological fingerprint, the upstream drivers — and many of the most promising interventions — overlap significantly.

This article (Part 1) covers pathophysiology, repurposed drugs, antiparasitic and antibiotic agents, iron dysregulation, DMSO, and BBB-crossing supplements. See Part 2 for chronic infection triggers (EBV, Bartonella, Babesia, Rickettsia, HSV-1, CMV, HHV-6) and comprehensive diagnostic testing panels.

Category 1: Amyotrophic Lateral Sclerosis (ALS)

Pathophysiology

• TDP-43 and FUS protein aggregation — misfolded proteins accumulate in motor neurons, disrupting RNA processing and triggering neuronal death.
• Glutamate excitotoxicity — excess synaptic glutamate overwhelms NMDA receptors, causing calcium influx and neuronal apoptosis.
• Mitochondrial dysfunction — impaired Complex I activity reduces ATP production and increases reactive oxygen species (ROS).
• Neuroinflammation — activated microglia and astrocytes release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), accelerating motor neuron loss.
• Gut-brain axis dysbiosis — emerging evidence links ALS progression to altered gut microbiome composition and increased intestinal permeability. (Blacher et al., Nature, 2019)

Repurposed Drugs Showing Promise in ALS

• Riluzole — FDA-approved; reduces glutamate excitotoxicity. Modest survival benefit (~3 months median).
• Edaravone (Radicava) — FDA-approved free radical scavenger. Slows functional decline in early-stage ALS.
• Low-Dose Naltrexone (LDN) — modulates microglial activation; downregulates TLR4-mediated neuroinflammation. (Younger et al., Pain Medicine, 2014)
• Methylene Blue — bypasses Complex I/III dysfunction; reduces ROS. Preclinical ALS neuroprotection.
• Rapamycin — mTOR inhibitor; upregulates autophagy to clear TDP-43/FUS aggregates.
• Masitinib — tyrosine kinase inhibitor targeting mast cells/microglia. Phase 2/3 showed significant slowing of ALS progression. (AB Science, 2021)
• Tofacitinib (JAK inhibitor) — reduces JAK-STAT neuroinflammatory signaling. Human trials ongoing.
• Sodium Phenylbutyrate + TUDCA — CENTAUR Phase 2 trial showed slowed functional decline. (Paganoni et al., NEJM, 2020)

Anecdotal Formularies & Patient-Reported Protocols

• The Deanna Protocol — AAKG, GABA, CoQ10, MCTs, hyperbaric oxygen. Anecdotal stabilization reports over 2+ years.
• Eric Edney Protocol — high-dose antioxidants, LDN, dietary ketosis. Self-reported stabilization documented in patient advocacy communities.

Category 2: Multiple Sclerosis (MS)

Pathophysiology

• Molecular mimicry — immune cells primed against EBV/HHV-6 cross-react with myelin basic protein (MBP).
• Blood-brain barrier breakdown — inflammatory cytokines degrade tight junctions, allowing peripheral immune infiltration.
• Remyelination failure — oligodendrocyte precursor cells (OPCs) fail to differentiate and repair damaged myelin.
• Mitochondrial dysfunction — axonal energy failure in demyelinated axons accelerates neurodegeneration.

Repurposed Drugs Showing Promise in MS

• Low-Dose Naltrexone (LDN) — improved QoL, reduced fatigue, possible neuroprotection. (Cree et al., Annals of Neurology, 2010)
• Metformin — promotes OPC differentiation and remyelination via AMPK. (Neumann et al., Cell Stem Cell, 2019)
• Clemastine — OPC differentiation; Phase 2 ReBUILD trial showed improved remyelination biomarker. (Green et al., Lancet, 2017)
• Simvastatin — reduced brain atrophy in secondary progressive MS. (Chataway et al., Lancet, 2014)
• Ibudilast — PDE4/10 inhibitor; SPRINT-MS trial showed reduced brain atrophy. (Fox et al., NEJM, 2018)
• Alpha-Lipoic Acid (high dose) — Phase 2 trial showed reduced brain atrophy in secondary progressive MS. (Spain et al., Journal of Neurology, 2017)

Category 3: Related Neurodegenerative Conditions

Parkinson's Disease (PD)

• Nilotinib — promotes autophagy; clears alpha-synuclein. Georgetown trials showed biomarker improvement. (Pagan et al., JAMA Neurology, 2020)
• GLP-1 agonists (Semaglutide, Liraglutide) — neuroprotective; reduced PD incidence in diabetic patients. (Brauer et al., NEJM Evidence, 2024)
• Ambroxol — GCase activator; reduces lysosomal dysfunction and alpha-synuclein. Phase 2 positive.

Alzheimer's Disease (AD)

• Rapamycin — reduces amyloid and tau pathology in preclinical models.
• Methylene Blue — tau aggregation inhibitor. Phase 3 trials mixed but mechanistically active.
• GLP-1 agonists — reduce neuroinflammation and amyloid burden; large RCTs underway.

Category 4: Emerging & Repurposed Agents — Antiparasitic, Antibiotic, and Anti-inflammatory Drugs

Niclosamide

• Wnt/β-catenin inhibition — reduces neuroinflammatory signaling and microglial hyperactivation.
• mTORC1 inhibition / autophagy induction — clears TDP-43, FUS, and alpha-synuclein aggregates.
• STAT3 inhibition — reduces astrocyte-driven neuroinflammation; relevant to ALS and MS.
• ALS preclinical data — SOD1 and TDP-43 mouse models show reduced motor neuron loss with niclosamide ethanolamine (NEN). (Bhatt et al., Neurotherapeutics, 2021)
• BBB note — NEN salt form and nanoparticle formulations significantly improve CNS bioavailability.

Mebendazole — Polymorph C

Polymorph C is the bioavailable crystalline form — polymorphs A and B have poor oral absorption and are largely inactive systemically.

• Wnt pathway modulation — inhibits Wnt/β-catenin signaling, reducing neuroinflammation.
• Autophagy induction — promotes clearance of misfolded protein aggregates via AMPK/mTOR axis.
• Axonal transport — low-dose tubulin modulation may restore cytoskeletal function disrupted by TDP-43 in ALS.
• Dosing — 100–200mg BID with a fatty meal. Fenbendazole is a lower-cost veterinary equivalent.

Ivermectin

• P-gp inhibition — blocks the BBB efflux pump, enhancing CNS penetration of co-administered neuroprotective agents.
• Neuroinflammation reduction — inhibits NF-κB; reduces microglial activation. (Ci et al., Journal of Neuroinflammation, 2020)
• Alpha-synuclein disaggregation — in vitro disruption of alpha-synuclein fibrils relevant to PD.
• Dosing — 0.2–0.4mg/kg. Caution: high doses cause CNS toxicity via GABA-A agonism. Practitioner supervision required.

Antibiotics with Neuroprotective Properties

• Minocycline — inhibits microglial activation and caspase-dependent apoptosis. ALS Phase 3 trial negative at doses tested; combination protocols remain of interest.
• Doxycycline — MMP inhibition preserves BBB integrity; neuroprotection in TBI/stroke models.
• Rifampicin — inhibits amyloid and alpha-synuclein aggregation in vitro.
• Azithromycin — NF-κB inhibition and autophagy induction; preclinical MS models show reduced demyelination.

NSAIDs and COX Inhibitors

• Celecoxib — COX-2 inhibition reduces PGE2-driven neuroinflammation. ALS mouse models show reduced motor neuron loss. (Drachman et al., Annals of Neurology, 2002)
• Indomethacin — COX inhibition + PPARγ agonism promotes microglial M2 polarization.
• Ibuprofen — epidemiological data associates regular use with reduced PD risk. (Chen et al., Neurology, 2005)

PrimeC (RL-1071)

Fixed-dose combination of extended-release ciprofloxacin + celecoxib developed by NeuroSense Therapeutics specifically for ALS.

• Ciprofloxacin component — modulates gut microbiome dysbiosis; reduces LPS-driven neuroinflammation; modulates TDP-43 RNA splicing in preclinical models.
• Celecoxib component — COX-2 inhibition reduces PGE2-driven motor neuron apoptosis.
• Phase 2a PARADIGM trial — statistically significant slowing of ALSFRS-R decline vs. placebo; reduced neurofilament light chain (NfL) biomarker. (NeuroSense Therapeutics, Journal of Neurology, 2023)
• Status — advancing to Phase 2b/3. Compassionate use may be available in select jurisdictions.

Iron Dysregulation and Ferroptosis in ALS

Iron dysregulation is a well-documented and mechanistically central feature of ALS. Elevated iron deposits have been detected in the motor cortex and spinal cord using quantitative susceptibility mapping (QSM) MRI, correlating with disease severity and progression rate.

Mechanisms

• Ferroptosis — iron-dependent, lipid peroxidation-driven cell death; primary motor neuron death pathway driven by GPX4 depletion. (Masaldan et al., Free Radical Biology and Medicine, 2019)
• TDP-43 / IRP2 dysregulation — TDP-43 aggregation impairs IRP2 mRNA binding, causing motor neuron iron overload.
• Fenton chemistry — free iron generates hydroxyl radicals (Fe²⁺ + H₂O₂ → OH•), causing catastrophic oxidative damage.
• Transferrin receptor upregulation — ALS neurons paradoxically import more iron despite existing overload.
• Hepcidin dysregulation — master iron regulatory hormone disrupted in ALS, contributing to systemic and CNS iron accumulation.

Iron Chelation Strategies

• Deferiprone — oral, BBB-crossing iron chelator. Phase 2 FAIRALS trial showed reduced motor cortex iron on MRI. (Moreau et al., JAMA Neurology, 2018)
• Deferoxamine — parenteral; used with DMSO in anecdotal protocols to enhance CNS delivery.
• Lactoferrin — iron-binding glycoprotein; crosses BBB via receptor-mediated transcytosis; anti-inflammatory; modulates gut microbiome. (Wang et al., Frontiers in Neuroscience, 2021)
• GPX4 support — selenium (selenomethionine) + Vitamin E tocotrienols to quench lipid peroxidation and support ferroptosis resistance.

Iron-Targeting Supplement Stack

• Lactoferrin (apo form, 300–600mg) — iron chelation + BBB penetration + gut microbiome support
• Selenium (selenomethionine, 100–200mcg) — GPX4 cofactor; ferroptosis resistance
• Vitamin E (mixed tocotrienols, 200–400mg) — lipid peroxidation quenching
• NAC (1200–2400mg) — glutathione precursor; supports GPX4 activity
• IP6 (Inositol hexaphosphate, 1–2g) — natural iron chelator; reduces labile iron pool
• Curcumin (liposomal) — iron chelation + NF-κB neuroinflammation reduction
• Avoid high-dose iron supplementation; minimize red meat in confirmed iron overload

DMSO in Neurological Disease

• BBB penetration — crosses the BBB and carries co-administered compounds, dramatically increasing CNS bioavailability.
• Anti-inflammatory — inhibits NF-κB; reduces prostaglandin synthesis; scavenges hydroxyl radicals.
• Protein disaggregation — disrupts TDP-43, tau, and alpha-synuclein aggregates.
• Iron chelation synergy — used as a carrier for deferoxamine in anecdotal ALS protocols.
• ALS — topical/IV DMSO + antioxidants (Vitamin C, glutathione). Anecdotal stabilization reports. No large RCTs.
• MS — historical use by Dr. Jacob (1960s–1980s). Topical application to spine reported to reduce spasticity.
• TBI — IV DMSO used clinically to reduce intracranial pressure. (de la Torre et al., 1983)
• Pharmaceutical-grade (99.9% pure) only. Dilute to 50–70% topically. Ensure clean skin. IV requires practitioner supervision.

BBB-Crossing Supplements with Neuroprotective Evidence

Integrative Protocol Framework

Foundation Layer (All Neurodegenerative Conditions)

• Mitochondrial: CoQ10/Ubiquinol (400–600mg), PQQ (20mg), Methylene Blue (0.5–1mg/kg)
• Antioxidant network: ALA (600–1200mg), NAC (1200–2400mg), Liposomal Glutathione (500mg), Liposomal Vitamin C (2–4g)
• Neuroinflammation: Omega-3 DHA (2–4g), Curcumin liposomal (1–2g), Resveratrol (500mg–1g)
• Membrane integrity: Phosphatidylserine (300mg), Magnesium L-Threonate (2g)
• Immune modulation: Vitamin D3 (5,000–10,000 IU + K2), LDN (1.5–4.5mg)
• Iron management: Lactoferrin (300–600mg), Selenium (100–200mcg), Vitamin E tocotrienols (200–400mg), IP6 (1–2g)

ALS-Specific Additions

• AAKG + MCT Oil / Ketogenic diet (Deanna Protocol)
• Sodium Phenylbutyrate + TUDCA (CENTAUR trial protocol)
• Masitinib — compassionate use or clinical trial
• PrimeC (ciprofloxacin + celecoxib) — Phase 2a validated
• Niclosamide ethanolamine (NEN) — mTOR/autophagy/STAT3 (preclinical; practitioner supervision)
• Deferiprone — BBB-crossing iron chelation (Phase 2 FAIRALS data)
• Ivermectin (low dose) — P-gp inhibition for enhanced CNS drug delivery

MS-Specific Additions

• Clemastine (1mg BID) — OPC differentiation and remyelination
• Metformin (500–1000mg) — OPC support and AMPK activation
• Lion's Mane (1–2g standardized) — NGF and remyelination
• B12 Methylcobalamin (1500–5000mcg) — myelin synthesis
• Mebendazole polymorph C (100mg BID with fat) — Wnt/autophagy modulation
• Doxycycline — MMP inhibition; BBB integrity
• Valacyclovir — if EBV/HSV-1 reactivation confirmed (see Part 2)

DMSO Integration

• Topical DMSO (50–70%) applied to spine/scalp as carrier for antioxidants
• DMSO + deferoxamine (topical) — anecdotal iron chelation protocol for ALS
• Pharmaceutical-grade only; clean skin required before application

Important Disclaimer

The information presented in this article is for educational purposes only and does not constitute medical advice. Neurodegenerative diseases are serious conditions requiring individualized medical management. Repurposed drugs and off-label protocols should only be pursued under the supervision of a qualified healthcare practitioner. Always consult your neurologist or integrative medicine physician before initiating any new protocol.

Continue to Part 2: Chronic Infections as Root Cause Triggers (EBV, Bartonella, Babesia, Rickettsia, HSV-1, CMV, HHV-6, Lyme) and Comprehensive Diagnostic Testing Panels →

Key References

• Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572:474–480.
• Paganoni S, et al. Trial of Sodium Phenylbutyrate–Taurursodiol for ALS. NEJM. 2020;383:919–930.
• Green AJ, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis. Lancet. 2017;390:2481–2489.
• Fox RJ, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. NEJM. 2018;379:846–855.
• Chataway J, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis. Lancet. 2014;383:2213–2221.
• Pagan FL, et al. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. JAMA Neurology. 2020;77:309–322.
• Neumann B, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25:473–485.
• Spain R, et al. Lipoic acid in secondary progressive MS. Journal of Neurology. 2017;264:2188–2198.
• Moreau C, et al. Deferiprone for Parkinson's disease. JAMA Neurology. 2018;75:448–455.
• Masaldan S, et al. Ferroptosis in ALS. Free Radical Biology and Medicine. 2019;133:221–232.
• Bhatt DL, et al. Niclosamide ethanolamine in ALS models. Neurotherapeutics. 2021.
• Ci X, et al. Ivermectin inhibits LPS-induced neuroinflammation. Journal of Neuroinflammation. 2020;17:1–12.
• Wang B, et al. Lactoferrin as a neuroprotective agent. Frontiers in Neuroscience. 2021;15:657042.
• NeuroSense Therapeutics. PrimeC Phase 2a PARADIGM trial results. Journal of Neurology. 2023.
• Drachman DB, et al. Cyclooxygenase 2 inhibition protects motor neurons in ALS. Annals of Neurology. 2002;52:771–778.
• Chen H, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neurology. 2005;64:1259–1263.
• de la Torre JC, et al. Dimethyl sulfoxide in central nervous system trauma. Annals of the New York Academy of Sciences. 1983;411:12–23.
• Brauer R, et al. Glucagon-like peptide 1 receptor agonists and Parkinson's disease. NEJM Evidence. 2024.
• Ascherio A, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology. 2014;71:306–314.
• Williamson T, et al. Mebendazole polymorphic forms and bioavailability. Drug Development and Industrial Pharmacy. 2020.